The 5 Best Protein Bars a Fitness Expert Has Tested in 2025
Who it's best for: This bar is best for those who love chocolate and don't have nut allergies, since most of the bars consist of either peanut, cashew or almond butters. The chocolate chip cookie dough is my favorite flavor and has 12 grams of protein. These bars have more calories and sugar than some others on the list, so be mindful of that if you're trying to lose weight. I can vouch that one of these bars can keep me full for hours, so it's ideal if you're not going to be able to sit down to eat between meals.
Other flavors you can enjoy by Perfect Bar include: chocolate brownie, dark chocolate almond, salted caramel and chocolate hazelnut.
Who should avoid it: If you have a nut allergy or don't like a protein bar with a heavy nut profile, you may find this option to be too much. Additionally, if you don't want to have to refrigerate your protein bars, you're better off with one that is shelf-stable.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
22 minutes ago
- Yahoo
Minze Health Appoints Thomas Moore as President and Chief Executive Officer
ANTWERP, Belgium & MINNEAPOLIS, August 12, 2025--(BUSINESS WIRE)--Minze Health, a leader in digital diagnostics and therapeutics for urology, announced today that Thomas Moore has been appointed President and Chief Executive Officer, effective immediately. Moore brings over two decades of commercial leadership in medtech and a proven track record of driving growth, reimbursement, and global market expansion across the U.S. and Europe. Prior to joining Minze, Moore served as Chief Commercial Officer at GT Medical Technologies and executive leadership roles at Ablative Solutions and CVRx, where he played a central role in revitalizing trial enrollment, scaling commercial operations, and raising over $100M in venture funding. His leadership has accelerated pivotal clinical trials, launched novel therapies, and expanded reimbursement in key global markets. "Minze is uniquely positioned to redefine the patient pathway for millions affected by BPH and OAB through our home-based diagnostics and evidence-backed therapeutics," said Moore. "I'm honored to join this world-class team and lead our expansion into the U.S. while advancing strategic partnerships, reimbursement access, and product innovation. The opportunity to make urologic care more accurate, efficient, and accessible has never been more urgent or exciting." Moore's appointment marks a new chapter in Minze's growth trajectory, as the company prepares for commercial scaling, key reimbursement milestones, and Series B fundraising. "Tom is the right leader at the right time," said Steffen Hovard, Executive Chairman of the Board. "He brings a powerful combination of strategic vision, commercial discipline, and passion for patient-centered innovation. We're thrilled to welcome him as CEO and confident he'll accelerate Minze's mission to become the global standard in digital urology care." About Minze Health Minze Health is transforming urology by combining accurate at-home diagnostics, remote monitoring, and digital therapeutics into a single, scalable platform. With CE mark and 510(k) exemptions, Minze's ecosystem supports early diagnosis and personalized care for conditions like BPH and OAB—empowering patients and relieving pressure on overburdened urology systems. For more information, visit View source version on Contacts Media Contact: Thomas MooreCEO, Minze HealthEmail: Phone: +1 763.258.9039 Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
Yahoo
22 minutes ago
- Yahoo
SafeRide Health Ranks No. 358 on the 2025 Inc. 5000 List of America's Fastest-Growing Private Companies
With Three-Year Revenue Growth of 1,118% Percent, SafeRide is redefining transportation as a trusted care delivery lever for Medicaid and Medicare Advantage plans. NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today announced that SafeRide Health is ranked No. 358 on the 2025 Inc. 5000 list, placing it among the top 7% of the fastest-growing private companies in America. SafeRide also earned distinctions as No. 5 in the San Antonio metro area, No. 40 in Texas, and No. 41 in the healthcare sector nationally. The Inc. 5000 provides a data-driven snapshot of the most successful companies within the economy's most dynamic segment—independent, entrepreneurial businesses. Past honorees include companies such as Microsoft, Meta, Chobani, Under Armour, Timberland, Oracle, and Patagonia. "We're honored to be named to the Inc. 5000 list, let alone to the top 500," said Robbins Schrader, CEO and Co-Founder of SafeRide Health. "We've built a team that shows up every day for the members of our partner health plans. This recognition is a tribute to their grit, to their hard work, and to the mission we share: fixing healthcare by getting people to care." SafeRide Health's ranking reflects more than just scale; it represents a transformation in how health plans are closing the gap between healthcare need and access. The company delivers more than 10 million rides annually across all 50 states, partnering with leading Medicaid and Medicare Advantage plans to serve members who depend on timely, reliable, and compliant non-emergency medical transportation. Unlike legacy brokers, SafeRide was built from the ground up to solve problems of fragmentation, missed care, and fraud, waste, and abuse (read related case study). It boasts industry-leading performance metrics, including 99% ride fulfillment and grievance rate below 0.25% of rides, and a platform that combines real-time eligibility, smart trip orchestration, and a credentialed national network to turn transportation into a care-experience lever. That people-first approach has earned national recognition, including a 2025 USA Today Top Workplace award as well as Top Workplace awards for Professional Development, Employee Well-Being, Culture Excellence, and Remote Work—affirming SafeRide's culture as a key driver of its growth and operational excellence. This year's Inc. 5000 honorees have demonstrated exceptional growth while navigating economic uncertainty, inflationary pressure, and a fluctuating labor market. Among the top 500 companies on the list, the median three-year revenue growth rate reached 1,552 percent, and those companies have collectively added more than 48,678 jobs to the U.S. economy over the past three years. For the full list, company profiles, and a searchable database by industry and location, visit: "Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company's tenacity and clarity of vision," says Mike Hofman, editor in chief of Inc. "These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn't just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy." Inc. will celebrate the honorees at the 2025 Inc. 5000 Conference & Gala, taking place October 22–24 in Phoenix, and the top 500 will be listed in the Fall issue of Inc. magazine. Methodology Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2024. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2021 is $100,000; the minimum for 2024 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons. About Inc. Inc. is the leading media brand and playbook for the entrepreneurs and business leaders shaping our future. Through its journalism, Inc. aims to inform, educate, and elevate the profile of its community: the risk-takers, the innovators, and the ultra-driven go-getters who are creating the future of business. Inc. is published by Mansueto Ventures LLC, along with fellow leading business publication Fast Company. For more information, visit About SafeRide HealthSafeRide Health is a technology and services company dedicated to closing the gap between healthcare need and access through modern, scalable non-emergency medical transportation (NEMT). Built for Medicaid and Medicare Advantage populations, SafeRide combines proprietary technology, real-time eligibility, and a nationwide network of credentialed transportation providers to deliver reliable, compliant, and compassionate care access at scale. Trusted by the country's largest payers and provider organizations, SafeRide transforms transportation from a cost center into a strategic lever for outcomes, equity, and member experience. Learn more at Media ContactAshley RobertsSafeRide Health(855) 955-7433mediarelations@ View original content to download multimedia: SOURCE SafeRide Health Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
PureTech Announces the Launch of Celea Therapeutics With a Mission to Transform the Treatment of Respiratory Diseases
Former Teva North America CEO Sven Dethlefs, PhD, to lead Celea BOSTON, August 12, 2025--(BUSINESS WIRE)--PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, today announced the launch of a new Founded Entity Celea Therapeutics ("Celea"). Celea's mission is to deliver therapies that transform the lives of people with serious respiratory diseases. Its lead program, deupirfenidone (LYT-100), is a Phase 3-ready therapeutic candidate that holds promise across multiple fibrotic and inflammatory lung conditions and is initially being advanced for the treatment of idiopathic pulmonary fibrosis (IPF), a rare, progressive, and fatal lung disease. Sven Dethlefs, PhD, has been appointed to lead Celea, bringing deep expertise and a clear vision to accelerate the program's advancement. The launch of Celea reflects PureTech's commitment to advancing differentiated programs through focused, capital-efficient structures with seasoned leadership. Dr. Dethlefs is a proven pharmaceutical executive with more than 25 years of experience in global commercialization, R&D strategy, business development, and operations. He has played a central role at PureTech, driving forward the deupirfenidone program for more than a year. Prior to joining PureTech, Dr. Dethlefs served as CEO of Teva North America, where he oversaw the company's $8 billion specialty branded and generic businesses across the U.S. and Canada. At Teva, he also held senior leadership roles as Global Head of Marketing and Portfolio, Head of Respiratory Medicines, and COO Operations. He played a key role in the successful launch of AUSTEDO®, Teva's blockbuster treatment for Tardive Dyskinesia and Huntington's Disease, which is a deuterated form of tetrabenazine. Prior to joining Teva, Dr. Dethlefs was a partner at McKinsey & Company. He holds a PhD in Biochemistry. Dr. Sven Dethlefs commented: "Bringing meaningful innovation to patients with serious diseases has been a consistent theme throughout my career, and I believe deupirfenidone has the potential to be a true turning point in the treatment of IPF. Our Phase 2b data demonstrated the potential for best-in-class efficacy with a favorable safety and tolerability profile—addressing two of the most critical limitations of current therapies. The strength of the clinical data, combined with the team and mission behind Celea, make this a uniquely compelling opportunity. I'm excited to lead the next phase of development as we work to deliver a new standard of care for people living with IPF and other debilitating lung conditions." PureTech completed a successful Phase 2b trial of deupirfenidone in December 2024. A meeting with the U.S. Food and Drug Administration to discuss these results and the proposed Phase 3 trial design is expected by the end of the third quarter of 2025. Consistent with its capital-efficient innovation model, PureTech is pursuing third-party funding for Celea to advance the program through Phase 3 and potential commercialization. Robert Lyne, PureTech's Interim Chief Executive Officer, added: "The launch of Celea is an important value driver for PureTech. Sven brings deep experience in respiratory medicine and a strong track record of commercial success, including having played a critical role in the growth of AUSTEDO®, a deuterated medicine developed using the same underlying chemistry approach as deupirfenidone. He is uniquely suited to lead Celea and advance this important program." About Deupirfenidone (LYT-100)Deupirfenidone (LYT-100) is in development as a potential new standard of care for the treatment of idiopathic pulmonary fibrosis (IPF). It is a deuterated form of pirfenidone, which – along with nintedanib – is one of the two FDA-approved treatments for IPF. Both approved therapies offer only modest efficacy in slowing lung function decline, largely due to tolerability challenges that limit the ability to achieve higher doses that could significantly improve patient outcomes. These limitations have contributed to low treatment uptake and poor adherence, with approximately 25% of people with IPF in the U.S. ever receiving either drug. Despite this, combined peak global sales exceed $5 billion, representing a significant market opportunity in IPF and other fibrotic lung diseases. 1 Deupirfenidone may overcome these limitations. In the global Phase 2b ELEVATE IPF trial, deupirfenidone demonstrated the potential to stabilize lung function decline over at least 26 weeks as a monotherapy while maintaining a favorable safety and tolerability profile. Initial data from an ongoing open-label extension study suggest that this effect may be sustained through at least 52 weeks. These findings support the potential for deupirfenidone to offer a meaningful advance for people living with this progressive and deadly disease. Beyond IPF, deupirfenidone may also address multiple underserved fibrotic conditions, including progressive fibrosing interstitial lung diseases. About Idiopathic Pulmonary Fibrosis (IPF)Idiopathic pulmonary fibrosis (IPF) is a rare, progressive, and fatal lung disease characterized by irreversible scarring of lung tissue that leads to a steady decline in lung function. Median survival following diagnosis is estimated to be two to five years, and currently there is no cure.2 About Celea TherapeuticsCelea Therapeutics is dedicated to delivering transformative treatments for people with serious respiratory diseases. The company's lead program, deupirfenidone (LYT-100), is a Phase 3-ready therapeutic candidate with the potential to set a new standard of care for idiopathic pulmonary fibrosis (IPF) and other fibrotic lung diseases. Celea was founded by PureTech Health plc (Nasdaq: PRTC, LSE: PRTC), a biotherapeutics company dedicated to giving life to science. PureTech's innovative R&D model drives the creation of Founded Entities like Celea, enabling the advancement of highly promising medicines to patients in a capital-efficient manner. For more information, please visit and About PureTech HealthPureTech is a clinical-stage biotherapeutics company dedicated to giving life to new classes of medicine to change the lives of patients with devastating diseases. The Company has created a broad and deep portfolio through its experienced research and development team and its extensive network of scientists, clinicians, and industry leaders that is being advanced both internally and through its Founded Entities. PureTech's R&D engine has resulted in the development of 29 therapeutics and therapeutic candidates, including three that have been approved by the U.S. Food and Drug Administration. A number of these programs are being advanced by PureTech or its Founded Entities in various indications and stages of clinical development, including registration-enabling studies. All of the underlying programs and platforms that resulted in this portfolio of therapeutic candidates were initially identified or discovered and then advanced by the PureTech team through key validation points. For more information, visit or connect with us on X (formerly Twitter) @puretechh. 1 Esbriet peak sales (2020) per Roche 2021 Financial Results & Ofev peak sales (2024) per Boehringer Ingelheim 2024 Financial Results. Ofev sales include those for all approved indications – IPF, PF-ILD, and systemic sclerosis-associated interstitial lung disease (SSc-ILD). 2 Fisher, M., Nathan, S. D., Hill, C., Marshall, J., Dejonckheere, F., Thuresson, P., & Maher, T. M. (2017). Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. Journal of Managed Care & Specialty Pharmacy, 23(3-b Suppl), S17–S24. Cautionary Note Regarding Forward-Looking StatementsThis press release contains statements that are or may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements that relate to continued development of and regulatory interactions related to deupirfenidone, the potential of deupirfenidone in IPF and other indications, our expectations around our therapeutic candidates and approach towards addressing major diseases, our plans to advance our programs and deliver on our milestones, our future plans, prospects, developments, and strategies. The forward-looking statements are based on current expectations and are subject to known and unknown risks, uncertainties and other important factors that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks, uncertainties and other important factors described under the caption "Risk Factors" in our Annual Report on Form 20-F for the year ended December 31, 2024 filed with the SEC and in our other regulatory filings. These forward-looking statements are based on assumptions regarding the present and future business strategies of the Company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, we disclaim any obligation to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise. View source version on Contacts PureTech Public Relationspublicrelations@ Investor RelationsIR@ UK/EU Media Ben Atwell, Rob Winder+44 (0) 20 3727 1000puretech@ US Media Justin Chen+1 609 578 7230justin@ Sign in to access your portfolio
